Zensar Tech: Near-Term Delays, Profitability Intact

BUY

November 3, 2025 CMP: INR 798 | Target Price: INR 1,000

Expected Share Price Return: 25.4% | Dividend Yield: 1.2% | Potential Upside: 26.6%

Sector View: Neutral

Change in Estimates	~
Target Price Change	~
Recommendation	×
0	
Company Info	
BB Code	ZENT IN EQUITY
Face Value (INR)	2.0
52 W High/Low (INR)	985/558
Mkt Cap (Bn)	INR 181.3/ \$2.0
Shares o/s (Mn)	230.9
3M Avg. Daily Volume	405,158

Change in I	Estimate	S				
	FY26E				FY27E	
INR Bn	New	Old	Dev. (%)	New	Old	Dev. (%)
Revenues	57.2	56.3	1.5	61.9	61.8	0.1
EBIT	7.9	7.5	5.6	8.9	8.8	0.6
EBITM %	13.9	13.3	53 bps	14.3	14.2	6 bps
EPS	32.6	31.4	3.7	37.3	37.0	0.8

Actual vs CIE Estimates								
INR Bn	Q2FY26A	CIE Est.	Dev.%					
Revenue	14.2	14.2	0.0					
EBIT	1.9	1.8	7.6					
EBITM %	13.7	12.8	90 Bps					
PAT	1.8	1.8	4.0					

Key Financials					
INR Bn	FY24	FY25	FY26E	FY27E	FY28E
Revenue	49.0	52.8	57.2	61.9	68.3
YoY (%)	1.1	7.7	8.2	8.3	10.4
EBITDA	8.7	8.2	8.9	9.9	11.2
EBITDAM %	17.8	15.5	15.6	16.0	16.4
Adj PAT	6.7	6.5	7.5	8.6	9.8
FDEPS	29.1	28.4	32.6	37.3	42.7
ROE %	18.7	16.0	16.4	16.7	16.9
ROCE %	20.7	17.6	17.3	17.3	17.4
PE(x)	16.6	25.5	24.5	21.4	18.7

Shareholding Pattern (%)							
	Sept-25	Jun-25	Mar-25				
Promoters	49.03	49.06	49.07				
Flls	13.30	14.56	14.98				
DIIs	22.24	20.52	19.89				
Public	15.43	15.85	16.06				

Relative Performance (%)								
YTD	3Y	2Y	1Y					
BSE IT	21.0	12.7	(13.4)					
ZENT.	46.3	35.0	(3.9)					



Dhanshree Jadhav

Email: dhanshree.jadhav@choiceindia.com

Ph: +91 22 6707 9535

Avi Jhaveri

Email: avi.jhaveri@choiceindia.com

Ph: +91 22 6707 9901

Q2FY26 Technology Result Preview

Al Tailwinds to Drive Long-term Growth; Near-term Growth takes a Set Back

ZENT's performance in H1FY26 remained constrained by tariff-related concerns, which weighed on client tech spending in the TMT and MCS verticals. However, easing macro headwinds in H2FY26, along with ZENT's focused services-led growth, Al-driven solutions, and large deal wins, position it well relative to peers. Despite the near-term softness, the company remains committed to delivering sustainable, long-term profitable growth with mid-teen margin guidance supported by cost optimization initiatives. The near-term growth is likely to remain muted due to tariff concerns impacting the TMT vertical and delays in deal conversions. Thus, we expect Revenue/EBIT/PAT to grow at a CAGR of 9.0%/12.2%/14.7% over FY25-28E. Considering these near-term headwinds and peer valuation dynamics, we revise our target PE multiple downward to 25x (from 28x) and lower our Target Price to INR 1,000 (from INR 1,130), while maintaining our BUY rating based on FY27E-FY28E average EPS of INR 40.

Steady Q2 Performance Amidst Macroeconomic Weakness

- Reported Revenue for Q2FY26 stood at USD 162.8Mn up 0.5% QoQ and 4.2% YoY (vs CIE est. at USD 163Mn). The CC growth was up 3.4% YoY. In INR terms, revenue stood at INR 14,213Mn, up 2.6% QoQ.
- EBIT for Q2FY26 came at INR 1,948Mn, up 3.9% QoQ (vs CIE est. at INR 1,819Mn). EBIT margin was up 20bps QoQ to 13.7% (vs CIE est. at 12.8%).
- PAT for Q2FY26 came at INR 1,822Mn, remaining flat QoQ (vs CIE est. at INR 1,752Mn) led by lower other income.

Al-driven TCV reaches 28%; TMT Vertical Headwinds Remain

ZENT's deal momentum is increasingly driven by AI, contributes 28% to TCV, up from 21% in Q1FY26. In Q2FY26, the TCV declined 7.7% QoQ to USD 158.7Mn, with deals focused primarily on vendor consolidation and outcome-based engagements. Amongst verticals, Q2FY26 saw sequential CC growth in BFSI at 4.8%, and Healthcare at 3.9%, while Manufacturing & Consumer Services (MCS) declined marginally by 0.6%. TMT vertical declined by 10.2% in CC terms, due to a secular trend across the industry where companies are shifting investment from Opex to Capex for areas like GPUs and data centers. TMT accounted for 27.1% of revenues in FY24, which has now dropped to 20% in Q2 FY26. The company's strategy is to grow other parts of the business faster to reduce the exposure to the TMT vertical. Despite macroeconomic headwinds and cautious client spending, GenAl spends are strong and it's a key pivot for future competitiveness.

EBITDAM likely to Stay Within Mid-Teens Band

ZENT's EBITDA margin in Q2FY26 was 15.4%, an increase of 20bps QoQ. Management stated they are deeply committed to deliver mid-teens EBITDA margins consistently and are not under-investing in sales, capabilities, or platforms. The company's strategy is to deliver higher revenues with less headcount additions by leveraging AI and maintaining high utilization rates (84.8%). Employee headcount stood at 10,550 as of Q2FY26, net reduction of 70. Voluntary LTM attrition stood at 9.8%, remaining stable QoQ.

ZENT Ltd.	Q2 FY26	Q1 FY26	QoQ (%)	Q2 FY25	YoY (%)
Revenues (USD Mn)	163	162	0.5	156	4.2
Revenues (INR Mn)	14,213	13,850	2.6	13,080	8.7
EBIT (INR Mn)	1,948	1,875	3.9	1,713	13.7
EBIT Margin (%)	13.7	13.5	17 bps	13.1	61 bps
Other income	491	567	(13.4)	411	19.5
Interest	37	36	2.8	45	(17.8)
PBT	2,402	2,406	(0.2)	2,079	15.5
Tax	580	586	(1.0)	522	11.1
Adj. PAT (INR Mn)	1,822	1,820	0.1	1,557	17.0
FDEPS (INR)	7.9	7.9	0.1	6.8	16.3

Management Call - Highlights

- ZENT's strategy remains clear: Client Centricity, Adapt to global shifts, and lead with Al. Management sees Al not as a threat, but as a big opportunity. It launched the Zensar Al Agentic Al platform to drive enterprise-level innovation and intelligence.
- 28% of the company's order bookings this quarter were Al influenced, defined as deals where they led with an Al-infused solution. This is up from 21% compared to Q1FY26.
- Over the last four months, more than 5,000 people have deepened their skills in AI, Gen AI, and Agentic AI through multi-tiered learning journeys. They are also creating a pool of strong strategic consultants to guide clients on their AI-first transformation journey.
- The Gen AI platform is finding resonance among clients, with traction in areas like legacy modernization and industry-specific agents (e.g., real-time AI powered fraud analytics, reducing workload by 40%).
- Q3 is expected to be a weak quarter due to furloughs. However, management is hopeful that the reduced exposure to TMT means the furlough impact might be less severe compared to competitors.
- Management stated that clients are generally cautious in an uncertain macroeconomic environment, focusing on mostly non-discretionary projects. However, Al-related discretionary spend is being welcome by clients. ZENT is utilizing Al productivity gains as a competitive lever, sharing benefits significantly with clients, rather than using it solely for productivity edge.
- It confirmed that they are not heavily H-1B dependent, with less than 3% of the overall workforce using H-1B visas, as they consciously try to hire locally.
- The CEO acknowledged that the slow Q2 growth was a surprise. While noting the company's strong relative growth performance in FY25 (ranking 4th in INR terms among peers), market headwinds will impact overall growth acceleration. Management remains confident in converting their strong pipeline in the next couple of quarters.

28% of the company's order bookings this quarter were AI influenced, defined as deals where they led with an AI-infused solution. This is up from 21% compared to Q1FY26.

Management stated that clients are generally cautious in an uncertain macroeconomic environment, focusing on mostly non-discretionary projects. However, only Alrelated discretionary spend is being welcome by clients.




Sequential Operating Performance

Sequential Operating Performance									
	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	
Income Statement									
Revenues (USD Mn)	145	148	154	156	157	157	162	163	
Revenues (INR Mn)	12,041	12,297	12,881	13,080	13,256	13,589	13,850	14,213	
Gross Profit (INR Mn)	2,806	2,833	3,054	2,841	3,028	2,967	3,157	3,003	
Gross Margin (%)	23.3	23.0	23.7	21.7	22.8	21.8	22.8	21.1	
EBITDA (INR Mn)	2,076	2,030	1,962	2,010	2,070	2,125	2,106	2,200	
EBITDA Margin (%)	17.2	16.5	15.2	15.4	15.6	15.6	15.2	15.5	
PAT (INR Mn)	1,617	1,733	1,579	1,557	1,598	1,764	1,820	1,822	
FDEPS (INR)	7.08	7.59	6.91	6.82	6.98	7.68	7.92	7.93	
Operating Metrics									
Revenue - Geography (%)									
North America	66.0	67.2	68.7	67.6	67.3	67.4	68.3	66.6	
Europe	21.4	20.8	19.8	21.1	21.2	21.4	20.5	21.5	
Africa	12.5	12.0	11.5	11.3	11.5	11.2	11.2	11.9	
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	
Revenue - Segments (%)									
TMT (Telecom-Media-Technology)	25.9	25.5	24.7	22.4	21.4	21.7	22.3	20.0	
MCS (Mfg. & Consumer Services)	26.1	26.3	25.8	26.2	27.7	26.7	25.3	25.2	
BFS (Banking & Financial Services)	38.6	38.7	39.7	40.9	40.1	41.0	41.5	43.6	
Healthcare & Life Sciences	9.4	9.5	9.8	10.5	10.8	10.6	10.9	11.2	
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	
Employee Metrics									
Total Headcount	10,225	10,349	10,396	10,240	10,517	10,702	10,620	10,550	
Attrition Rate LTM (%)	12.0	10.9	10.6	10.1	10.0	9.9	9.8	9.8	
Trainees(%)	80.7	83.7	83.9	82.8	82.9	84.6	84.3	84.8	
Revenue Split (%)									
Onsite	50.4	50.0	51.4	49.7	49.5	49.0	47.4	45.8	
Offshore	49.6	50.0	48.6	50.3	50.5	51.0	52.6	54.2	
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	

Choice Institutional Equities

Revenue up 0.5% sequentially due to weak macros




Source: ZENT, Choice Institutional Equities

Revenue expected to expand at 9.0% CAGR over FY25-28E




Source: ZENT, Choice Institutional Equities

EBITDAM within comfortable mid-teens band




Source: ZENT, Choice Institutional Equities

EBITDA expected to grow at 11.1% CAGR over FY25-28E




Source: ZENT, Choice Institutional Equities

PATM declined to 12.8% led by lower other income




Source: ZENT, Choice Institutional Equities

PAT expected to grow at 14.7% CAGR over FY25-28E




Choice Institutional Equities

Attrition rate declined to 9.8%




Source: ZENT, Choice Institutional Equities

BFS vertical revenue share continued to expand




Source: ZENT, Choice Institutional Equities

Growth was led by UK & South Africa Markets




Source: ZENT, Choice Institutional Equities

Onsite & Offshore mix




Source: ZENT, Choice Institutional Equities

ROE & ROCE trend



Source: ZENT, Choice Institutional Equities

1 Year Forward PE Band





Income Statement (Consolidated in INR Mn)

	`			,	
Particular	FY24	FY25	FY26E	FY27E	FY28E
Revenue (USD Mn)	592	624	655	703	776
Revenue	49,019	52,806	57,161	61,882	68,304
Gross profit	11,843	11,890	12,828	14,251	16,052
EBITDA	8,717	8,167	8,905	9,874	11,202
Depreciation	1,338	1,019	988	1,022	1,097
EBIT	7,379	7,148	7,917	8,852	10,105
Other income	1,588	1,602	2,123	2,632	3,016
Interest expense	209	173	147	130	120
PAT	6,650	6,498	7,481	8,572	9,816
EPS	29.1	28.4	32.6	37.3	42.7

Ratio Analysis	FY24	FY25	FY26E	FY27E	FY28E
Growth Ratios (%)					
Revenues (USD)	(2.0)	5.4	5.0	7.3	10.4
Revenues (INR)	1.1	7.7	8.2	8.3	10.4
EBITDA	57.9	(6.3)	9.0	10.9	13.5
EBIT	99.9	(3.1)	10.8	11.8	14.2
Margin Ratios (%)					
EBITDA Margin	17.8	15.5	15.6	16.0	16.4
EBIT Margin	15.1	13.5	13.9	14.3	14.8
Profitability (%)					
ROE	18.7	16.0	16.4	16.7	16.9
ROIC	19.5	16.1	16.2	16.4	17.2
ROCE	20.7	17.6	17.3	17.3	17.4
Financial Leverage					
OCF / Net profit (%)	73.7	69.2	66.8	70.1	72.7
EV/ EBITDA (x)	11.0	17.7	18.0	16.0	13.9
BVPS (x)	157.3	179.3	201.2	226.0	255.2
Free Cash Flow Yield(%)	5.7	3.2	2.6	3.3	3.9

Source: ZENT, Choice Institutional Equities


Balance Sheet (Consolidated in INR Mn)

Particular	FY24	FY25	FY26E	FY27E	FY28E			
Tangible fixed assets	863	914	919	919	919			
Goodwill & intangible assets	8,103	9,819	10,069	10,069	10,069			
Investments	18,077	20,387	20,887	21,887	22,887			
Cash & Cash equivalents	7,241	7,436	8,945	10,896	13,802			
Other non-current assets	-	-	-	-	-			
Other current assets	12,194	13,173	14,929	16,597	18,364			
Total Assets	46,478	51,729	55,749	60,368	66,041			
Shareholder's funds	35,619	40,697	45,679	51,298	57,933			
Minority interest	-	-	-	-	-			
Borrowings	-	-	-	-	-			
Other non-current liabilities	2,319	2,210	2,010	2,010	2,010			
Other current liabilities	8,540	8,822	8,060	7,060	6,060			
Total Equity & Liabilities	46,478	51,729	55,749	60,368	66,003			

Cash Flows (INR Mn)	FY24	FY25	FY26E	FY27E	FY28E
Cash Flows From Operations	6,421	5,650	5,951	6,926	8,145
Cash Flows From Investing	(4,751)	(4,877)	(2,160)	(2,973)	(4,002)
Cash Flows From Financing	(1,971)	(2,645)	(2,499)	(2,953)	(3,181)

DuPont Analysis	FY24	FY25	FY26E	FY27E	FY28E
Tax Burden	76%	76%	76%	76%	76%
Interest Burden	118.7%	120.0%	125.0%	128.3%	128.7%
EBIT Margin	15.1%	13.5%	13.9%	14.3%	14.8%
Asset Turnover	1.1	1.0	1.0	1.0	1.0
Equity Multiplier	1.3	1.3	1.2	1.2	1.1
ROE	18.7%	16.0%	16.4%	16.7%	16.9%

Historical share price chart: Zensar Technologies Limited



Date	Rating	Target Price
July 01, 2025	BUY	1,130
July 23, 2025	BUY	1,130
Novermber 3, 2025	BUY	1,000

Control December 7			
Institutional Research Team	Used of health dissel Deserve		104 00 6707 0440
Utsav Verma, CFA	Head of Institutional Research	utsav.verma@choiceindia.com	+91 22 6707 9440
Prashanth Kumar Kota, CFA	Analyst – Basic Materials	prashanth.kota@choiceindia.com	+91 22 6707 9887
Dhanshree Jadhav	Analyst – Technology	dhanshree.jadhav@choiceindia.com	+91 22 6707 9535
Karan Kamdar	Analyst – Small and Midcaps	karan.kamdar@choiceindia.com	+91 22 6707 9451
Deepika Murarka	Analyst – Healthcare	deepika.murarka@choiceindia.com	+91 22 6707 9513
Putta Ravi Kumar	Analyst – Defence	ravi.putta@choiceindia.com	+91 22 6707 9908
Maitri Sheth	Analyst – Pharmaceuticals	maitri.sheth@choiceindia.com	+91 22 6707 9511
Ashutosh Murarka	Analyst – Cement & Infrastructure	ashutosh.murarka@choiceindia.com	+91 22 6707 9887
Dhaval Popat	Analyst – Energy	dhaval.popat@choiceindia.com	+91 22 6707 9949
Aayush Saboo	Sr. Associate– Real Estate	aayush.saboo@choiceindia.com	+91 22 6707 9512
Bharat Kumar Kudikyala	Sr. Associate – Building Materials and Mining	bharat.kudikyala@choiceindia.com	+91 22 6707 9521
Avi Jhaveri	Sr. Associate – Technology	avi.jhaveri@choiceindia.com	+91 22 6707 9901
Kunal Bajaj	Sr. Associate – Technology	kunal.bajaj@choiceindia.com	+91 22 6707 9901
Abhinav Kapadia	Sr. Associate – Capital Goods	abhinav.kapadia@choiceindia.com	+91 22 6707 9707
Subhash Gate	Sr. Associate – Auto	subhash.gate@choiceindia.com	+91 22 6707 9233
Vikrant Shah, CFA (ICFAI)	Sr. Associate – Banks	vikrant.shah@choiceindia.com	+91 22 6707 9887
Vinay Rawal	Associate – Small and Midcaps	vinay.rawal@choiceindia.com	+91 22 6707 9433
Heer Gogri	Associate – Small and Midcaps	heer.gogri@choiceindia.com	+91 22 6707 9433
Heet Chheda	Associate – Auto	heet.chheda@choiceindia.com	+91 22 6707 9233
Rushil Katiyar	Associate – Technology	rushil.katiyar@choiceindia.com	+91 22 6707 9535
Stuti Bagadia	Associate – Pharmaceuticals	stuti.bagadia@choiceindia.com	+91 22 6707 9511

CHOICE RATING DIST	RIBUTION & METHODOLOGY
Large Cap*	
BUY	The security is expected to generate upside of 15% or more over the next 12 months
ADD	The security is expected to show upside returns from 5% to less than 15% over the next 12 months
REDUCE	The security is expected to show upside or downside returns by 5% to -5% over the next 12 months
SELL	The security is expected to show downside of 5% or more over the next 12 months
Mid & Small Cap*	
BUY	The security is expected to generate upside of 20% or more over the next 12 months
ADD	The security is expected to show upside returns from 5% to less than 20% over the next 12 months
REDUCE	The security is expected to show upside or downside returns by 5% to -10% over the next 12 months
SELL	The security is expected to show downside of 10% or more over the next 12 months
Other Ratings	
NOT RATED (NR)	The stock has no recommendation from the Analyst
UNDER REVIEW (UR)	The stock is under review by the Analyst and rating may change
Sector View	
POSITIVE (P)	Fundamentals of the sector look attractive over the next 12 months
NEUTRAL (N)	Fundamentals of the sector are expected to be in statis over the next 12 months
CAUTIOUS (C)	Fundamentals of the sector are expected to be challenging over the next 12 months

*Large Cap: More Than INR 20,000Cr Market Cap
*Mid & Small Cap: Less Than INR 20,000Cr Market Cap

Disclaimer

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Choice Equity Broking Private Limited-Research Analyst - INH000000222. (CIN. NO.: U65999MH2010PTC198714). Reg. Add.: Sunil Patodia Tower, J B Nagar, Andheri(East), Mumbai 400099. Tel. No. 022-6707 9999

Compliance Officer--Prashant Salian, Email Id - Prashant.salain@choiceindia.com Contact no. 022- 67079999- Ext-2310

Grievance officer-Deepika Singhvi Tel.022-67079999- Ext-834. Email- ig@choiceindia.comm

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

This Research Report (hereinafter referred as "Report") has been prepared by Choice Equity Broking Private Limited as a Research Entity (hereinafter referred as "CEBPL RE" Limited. The Research Analysts, strategists are principally responsible for the preparation of "CEBPL RE" research. The research analysts have received compensation based upon various factors, which may include quality of research, investor client feedback, stock picking, competitive factors and firm revenues etc.

Whilst CEBPL has taken all reasonable steps to ensure that this information is correct, CEBPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his or her own risk and CEBPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.



General Disclaimer: This 'Report' is strictly meant for use by the recipient and is not for circulation. This Report does not take into account particular investment objectives, financial situations or specific needs of individual clients nor does it constitute a personal recommendation. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through CEBPL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein.

These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this "Report" should rely on information/data arising out of their own Study/investigations. It is advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This 'Report' has been prepared on the basis of publicly available information, internally developed data and other sources believed by CEBPL to be reliable. CEBPL or its directors, employees, affiliates or representatives shall not be responsible for, or warrant for the accuracy, completeness, adequacy and reliability of such information / opinions / views. Though due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of CEBPL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this report.

The price and value of the investments referred to in this Report and the income from them may tend to go down as well as up, and investors may incur losses on any investments. Past performance shall not be a guide for future performance. CEBPL does not provide tax advice to its clients, and all investors are strongly advised to take advice of their tax advisers regarding taxation aspects of any potential investment. Opinions are based on the current scenario as of the date appearing on this 'Report' only. CEBPL does not undertake to advise you as to any change of our views expressed in this "Report' may differ on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold CEBPL, its employees and associates responsible for any losses, damages of any type whatsoever.

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject "CEBPL RE" to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by "CEBPL RE" in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this 'Report' shall not be possesed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. "CEBPL" requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to "CEBPL". Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in Mumbai (India).

Statements on ownership and material conflicts of interest, compensation - CEBPL and Associates reciprocates to the best of the knowledge and belief of CEBPL/ its Associates/ research Analyst who is preparing this report.

Disclosures of Interest (Additional):

- 1. "CEBPL", its research Analyst(s), or its associates or relatives of the Research Analyst does not have any financial interest in the company(ies) covered in this report.
- "CEBPL" its research Analyst, or its associates or relatives of the research analyst affiliates collectively do not hold more than 1 of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- 3. "CEBPL", its research analyst, his/her associate, his/her relative, do not have any other material conflict of interest at the time of publication of this research report.
- "CEBPL", its research analyst, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months
- 5. "CEBPL", its research analyst, or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report.
- "CEBPL, or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research 7.
- 8. CEBPL research analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Research report.
- "CEBPL", its research analyst has not been engaged in market making activity for the company(ies) covered in the Research report.

Details of Associates of CEBPL and Brief History of Disciplinary action by regulatory authorities are available on our

website i.e. https://choiceindia.com/research-listing

Sr. No.	Particulars Particulars	Yes / No
1.	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by CEBPL	No
2	Whether Research Analyst, CEBPL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1 of the company(ies) covered in the Research report	No
3.	Whether compensation has been received by CEBPL or its associates from the company(ies) covered in the Research report	No
4.	CEBPL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report	No
5.	CEBPL, its research analyst, his associate, or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve months	No

Copyright: The copyright in this research report belongs exclusively to CEBPL. All rights are reserved. Any unauthorized use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the CEBPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

This "Report" is for distribution only under such circumstances as may be permitted by applicable law. This "Report" has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This "Report" is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither CEBPL nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this "report" or lack of care in this report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Information barriers may be relied upon by CEBPL, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of CEBPL

Investing in any non-U.S. securities or related financial instruments (including ADINR) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by CEBPL with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of CEBPL and CEBPL accepts no liability whatsoever for the actions of third parties in this respect

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Research report are given above.